CSL Behring is a global leader in
developing and delivering high quality medicines that treat people with rare
and serious diseases. Working every day as if people¡¯s lives depend on it,
CSL¡¯s R&D fuels the company¡¯s sustainable growth by advancing world-class
science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma
fractionation, recombinant technology, and cell and gene therapy to develop and
deliver innovative medicines that address unmet medical needs or enhance
current treatments in five Therapeutic Areas - Immunology and Neurology, Hematology
and Thrombosis, Cardiovascular and Metabolic, Respiratory and Transplant. Our
R&D portfolio focuses on innovation in new products, improved products and
manufacturing expertise ensuring our continued growth.
Product
portfolio https://www.csl.com/research-and-development/product-pipeline